SkinBioTherapeutics PLC Product Development Progress (6861U)
July 31 2020 - 1:00AM
UK Regulatory
TIDMSBTX
RNS Number : 6861U
SkinBioTherapeutics PLC
31 July 2020
31 July 2020
SkinBioTherapeutics plc
("SkinBioTherapeutics" or "the Company" or "the Group")
Product Development Progress
-- Cosmetic programme achieves key scientific milestones with its partner Sederma (Croda)
-- Company targeting an accelerated psoriasis food supplement
trial in early 2021 to facilitate launch of AxisBiotix product
SkinBioTherapeutics plc (AIM: SBTX), a life science company
focused on skin health, provides an update on its product
development programmes.
Cosmetic skincare
Sederma, the division of Croda Plc that specialises in the
manufacture of bioactive ingredients for the cosmetic industry, has
updated the Company on progress of its ongoing collaboration and
confirmed that;
-- Sederma has successfully replicated the lysate manufacturing
process and achieved the same performance from the SkinBiotix(R)
technology as established by the Company
-- Sederma is now working to validate scale up of the
manufacturing process at different volume levels
-- The project is progressing in line with the original plan and
has not been adversely impacted by COVID-19.
Sederma will be responsible for the development, manufacture and
commercialisation of the SkinBiotix (R) technology, with any
products resulting from this programme being sold to Croda's global
portfolio of Personal Care customers. SkinBioTherapeutics will be
paid tiered royalties based on global sales revenues on any
licensed products derived from the partnership.
Acceleration of psoriasis food supplement trial
In February 2020, the Company signed a development agreement
with Winclove for a probiotic food supplement to help manage the
symptoms associated with the skin condition, psoriasis.
In July (RNS 7 July 2020) the Company reported that several
months ahead of schedule, Winclove had successfully combined and
formulated the blend as a probiotic food supplement, to be known as
AxisBiotix (TM)Ps.
In light of the current restrictions with regards to non-COVID
related human studies, the Company has established a protocol for,
and is proceeding with, a 'self-managed' food supplement trial.
Participants suffering from mild to moderate psoriasis will be
invited to participate in a human study in which they will be
provided with samples of AxisBiotix (TM)Ps to self-administer over
an eight week period and track the impact of the food supplement on
their skin condition. Participants will submit their findings on a
periodic basis through a bespoke mobile device app, thus avoiding
the need for clinical attendance. This will accelerate the timing
of readout compared to the previously envisaged conventional study.
As a result, if the findings are positive, this will allow for a
significantly earlier commercial launch than originally planned.
The Company anticipates commencing the trial in early 2021.
Stuart Ashman, CEO of SkinBioTherapeutics, said:
"We have seen significant positive progress made on the first of
our commercial programmes in recent weeks. In such an important
scientific milestone, it is reassuring and provides validation of
our approach that Sederma has been able to replicate the activity
of the SkinBiotix technology and is pushing ahead with the next
steps of the project.
"In addition, establishing a clear pathway to commencing a food
supplement trial to manage symptoms associated with psoriasis is a
great step forward for our collaboration with Winclove. The
progress made in such a short period of time is testament to the
combined efforts of the SkinBioTherapeutics and Winclove team."
-Ends-
The information communicated within this announcement is deemed
to constitute inside information as stipulated under the Market
Abuse Regulations (EU) No. 596/2014 and has been arranged for
release by Doug Quinn, CFO of the Company. Upon the publication of
this announcement, this inside information is now considered to be
in the public domain.
For more information please contact:
SkinBioTherapeutics plc Tel: +44 (0) 161
Stuart J . Ashman, CEO 468 2760
Doug Quinn, CFO
Cenkos Securities Plc (Nominated Adviser Tel: +44 (0) 20 7397
& Broker) 8900
Giles Balleny, Max Gould (Corporate Finance)
Michael Johnson (Sales)
Instinctif Partners Tel: +44 (0) 20 7457
Melanie Toyne-Sewell / Phillip Marriage 2020
/ Nathan Billis SkinBio@instinctif.com
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin
health. The Company's proprietary platform technology,
SkinBiotix(R), is based upon discoveries made by Prof. Catherine
O'Neill and Prof. Andrew McBain.
The Company has demonstrated, through scientific testing, that
the SkinBiotix(R) platform can improve the barrier effect of skin
models, protect from infection and repair wounds. Proof of
principle studies have also shown that the SkinBiotix(R) platform
has beneficial attributes applicable to each of these areas. The
technology achieved positive results in clinical studies in human
volunteers in early 2019.
The Company listed on AIM in April 2017 and is based in
Manchester, UK. For more information, visit: www.skinbiotix.com
.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
UPDWPURUMUPUPUU
(END) Dow Jones Newswires
July 31, 2020 02:00 ET (06:00 GMT)
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From Apr 2024 to May 2024
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From May 2023 to May 2024